Home » Clinical Trials » Search Clinical Trials
Parent Therapeutic Areas: Immunology/Infectious Diseases

Hepatitis B

California

Los Angeles : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Los Angeles : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Palo Alto : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

San Diego : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

San Francisco : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

San Jose : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Stanford : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Florida

Miami : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Georgia

Atlanta : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Illinois

Various Cities : Research Center New!

Hepatitis B Study CLDT600AUS06

Louisiana

New Orleans : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Massachusetts

Boston : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Michigan

Ann Arbor : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

New York

Flushing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

New York : Mount Sinai Medical Center

A Multi-center, Randomized, Double-Blind, Active-Control, 96 Week, Phase III Trial of the Efficacy and Safety of Clevudine Compared with Adefovir at Weeks 48 and 96 in Nucleoside Treatment-Naive Patients with HBeAg Positive Chronic Hepatitis due to Hepatitis B Virus

New York : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Rochester : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Various Cities : Research Center New!

Hepatitis B Study CLDT600AUS06

Oregon

Portland : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Pennsylvania

Philadelphia : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Texas

Various Cities : Research Center New!

Hepatitis B Study CLDT600AUS06

Virginia

Charlottesville : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Richmond : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Richmond : Research Site:

Prevention of Recurrent Hepatitis B After Liver Transplantation

Australia

Brisbane : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Fitzroy : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Fitzroy : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Austria

Innsbruck : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Vienna : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Brazil

Campinas : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Campinas : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Ribeirão Preto : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Ribeirão Preto : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Salvador : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Salvador : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Santo Andre : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Santo Andre : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Sao Paulo : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Sao Paulo : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Bulgaria

Plovdiv : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Sofia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Sofia : Research Site:

SOFIA-LTT Study: A Study of Intermittent Long Term Treatment With PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Negative Chronic Hepatitis B (CHB).

Stara Zagora : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Varna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

China

Beijing : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Beijing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Beijing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Beijing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Beijing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).

Chengdu : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Chongqing : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Fu Zhou : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Guangzhou : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Guangzhou : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Guangzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Guangzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Guangzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).

Hangzhou : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Hangzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Hangzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Hunan : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hunan : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Hunan : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Jinan : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Shanghai : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Shanghai : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Shanghai : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Shanghai : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Shanghai : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV).

Wuhan : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Xi'An : Research Site:

A Study of Combination or Sequential Treatment With PEGASYS (peginterferon alfa-2a (40KD))and Entecavir in Patients With HBeAg Positive Chronic Hepatitis B

Xi'An : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Zhengzhou : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Estonia

Tallinn : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Tartu : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

France

Bondy : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Clermont-Ferrand : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Clichy : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Clichy : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Creteil : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Grenoble : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Lille : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Marseille : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Montpellier : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Montpellier : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Nice : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Orleans : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Paris : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Pessac : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Saint Laurent Du Var : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Strasbourg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Toulouse : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Toulouse : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Villejuif : Research Site:

A Pilot Study of New-Onset Therapy With PEGASYS (Peginterferon alfa-2a (40KD)) in Pre-Treated Patients With Chronic Hepatitis B.

Villejuif : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Germany

Berlin : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Essen : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Frankfurt Am Main : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Freiburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Homburg : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Köln : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Oberhausen : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Greece

Aigaleo - Attiki : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)

Alexandroupolis : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)

Athens : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)

Athens : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Piraeus : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a(40KD)) in Patients With Chronic Hepatitis B Virus (HBV)

Thessaloniki : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Hong Kong

Hong Kong : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hong Kong : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Hong Kong : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Lamivudine-Resistant HBeAg-Positive Chronic Hepatitis B (HBV).

Hong Kong : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) Plus Entecavir in Treatment-Naive Patients With HBeAg-Positive Chronic Hepatitis B.

Italy

Augusta : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Bari : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Bologna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253

Bologna : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Brescia : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Cagliari : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Caserta : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Castellana Grotte : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Catania : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Galatina : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Messina : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Messina : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Milano : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253

Milano : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Napoli : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Padova : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Palermo : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Palermo : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Parma : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) Infection-Immunology Sub-Study of ML18253

Parma : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Pisa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

San Giovanni Rotondo : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Torino : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Udine : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Verona : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Korea, Republic of

Seoul : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Latvia

Riga : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Lithuania

Kaunas : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Klaipeda : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Vilnius : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B (CHB).

Netherlands

Rotterdam : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

New Zealand

Auckland : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Auckland : Research Site:

A Study of Early Immunologic Response in Asian Patients with Chronic Hepatitis B, Treated With Pegasys (Peginterferon alfa-2a (40KD)), Nucleoside Analogues, or Both

Auckland : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Auckland : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Auckland : Research Site:

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Christchurch : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hamilton : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Hamilton : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Hamilton : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

New Plymouth : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Rotorua : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B Virus (HBV) in an Expanded Access Program

Poland

Bialystok : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Bydgoszcz : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Krakow : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Poznan : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Wroclaw : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Romania

Bucharest : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Cluj-Napoca : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Constanta : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Iasi : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Timisoara : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg-Positive Chronic Hepatitis B Virus (HBV)

Russian Federation

Chelyabinsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Ekaterinburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Irkutsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Kazan : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Krasnoyarsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Moscow : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Nizhny Novgorod : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Novokuznetsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Novosibirsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Rostov-Na-Donu : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Samara : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Samara : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Samara : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Smolensk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

St Petersburg : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

St Petersburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

St Petersburg : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Stavropol : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Stavropol : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Stavropol : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Tomsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Tumen : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Ufa : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Volgograd : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Yakutsk : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With Chronic Hepatitis B.

Singapore

Singapore : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Singapore : Research Site:

A Study of Early Immunologic Response in Asian Patients with Chronic Hepatitis B, Treated With Pegasys (Peginterferon alfa-2a (40KD)), Nucleoside Analogues, or Both

Singapore : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Singapore : Research Site:

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Taiwan

Changhua : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Kaohsiung : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Kaohsiung : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Kaohsiung : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Taichung : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Taipei : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Taipei : Research Site:

A Study of Early Immunologic Response in Asian Patients with Chronic Hepatitis B, Treated With Pegasys (Peginterferon alfa-2a (40KD)), Nucleoside Analogues, or Both

Taipei : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Taipei : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Taipei : Research Site:

A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies

Taoyuan : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Taoyuan : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Combination With Adefovir or Entecavir in Patients With HBeAg-Positive Chronic Hepatitis B

Taoyuan : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Thailand

Bangkok : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Bangkok : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Chiang Mai : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Chiang Mai : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Khon Kaen : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Khon Kaen : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Songkhla : Research Site:

A Follow-Up Study to WV19432, to Evaluate Long Term Post-Treatment Effects of PEGASYS (Peginterferon alfa-2a(40KD))in Patients With HBeAg Positive Chronic Hepatitis B

Songkhla : Research Site:

A Study of PEGASYS (Peginterferon alfa-2a (40KD)) in Patients With HBeAg Positive Chronic Hepatitis B (CHB).

Turkey

Ankara : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Ankara : Research Site:

ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Ege : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection

Gaziantep : Research Site:

ADVANCE Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) + Adefovir Dipivoxil in Patients With Hbe(-) Chronic Hepatitis B

Istanbul : Research Site:

A Study of PEGASYS plus Ribavirin Combination Therapy in Patients with HBeAg-Negative Chronic Hepatitis B Infection